Recursion Pharmaceuticals Capital Raise of $200M
Recursion Pharmaceuticals entered into an underwriting agreement to raise approximately $200 million through a public offering of 61,540,000 shares of Class A common stock at $3.25 per share. The company also announced that Sanofi exercised an option for a first-in-class immunology development candidate under their existing collaboration, triggering a $10 million milestone payment. Proceeds from the equity raise are expected to extend the company's cash runway into 2029.
- Value
- $200M
- Counterparty
- Leerink Partners LLC